Clinical Trials Logo

Clinical Trial Summary

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma


Clinical Trial Description

CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may reduce the recurrence rate after treatment. This study was to evaluate the efficacy and safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03881761
Study type Interventional
Source Henan Cancer Hospital
Contact Yongping Song, Dr.
Phone +86-37165587795
Email songyongping2018@126.com
Status Recruiting
Phase Phase 1
Start date February 1, 2019
Completion date January 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Not yet recruiting NCT06424301 - Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma Early Phase 1
Active, not recruiting NCT02280993 - Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Phase 1
Completed NCT00752518 - A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT03085173 - A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Phase 1
Active, not recruiting NCT03179930 - Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Phase 2
Recruiting NCT03275493 - CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT05153330 - Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL Phase 1
Recruiting NCT03881774 - Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies Phase 1
Recruiting NCT02407275 - Rhinosinusites Chroniques N/A
Recruiting NCT05911321 - Isa-Pom-Dex in Elderly/Frail Subjects With RRMM Phase 2
Not yet recruiting NCT04599452 - NK Cell Therapy Recurrent/Refractory Elderly AML Phase 1/Phase 2
Recruiting NCT06090864 - ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Phase 1/Phase 2
Not yet recruiting NCT06265545 - Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia N/A